Stryker

Stryker EV/EBIT

The EV/EBIT (Enterprise Value to EBIT) of Stryker (SYK) as of Oct 18, 2026 is 26.01. In the previous year, EV/EBIT (Enterprise Value to EBIT) was 25.13 — a change of 3.52% (higher).

EV/EBIT

26.01

YoY

3.52%

Last updated:

EV/EBIT (Enterprise Value to EBIT) of Stryker is 2025 26.01 . EV/EBIT (Enterprise Value to EBIT) of Stryker was 2024 25.13 . It decreases by 3.52% higher compared to the previous year.

The Stryker EV/EBIT history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EV/EBIT
Date
EV/EBIT
Jan 1, 2019
37.53 USD
Jan 1, 2020
42.00 USD
Jan 1, 2021
33.79 USD
Jan 1, 2022
34.06 USD
Jan 1, 2023
29.71 USD
Jan 1, 2024
25.13 USD
Jan 1, 2025
26.01 USD
Jan 1, 2026 (e)
15.73 USD
The Stryker EV/EBIT history
YEAREV/EBITYoY
est15.73-39.53%
26.01+3.52%
25.13-15.41%
29.71-12.78%
34.06+0.78%
33.79-19.53%
42.00+11.89%
37.53-8.38%
40.97-10.86%
45.96-6.87%
49.35-12.61%
56.47-1.02%
57.05+316.74%
13.69+25.14%
10.94+13.02%
9.68-15.38%
11.44-2.14%
11.69+14.05%
10.25-56.44%
23.53+15.68%
20.34—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Stryker Valuation

Details

Historical Valuation Multiples

ⓘ

Price-to-Earnings Ratio (P/E)

The P/E ratio divides Stryker's share price by its earnings per share. It tells you how many years of current earnings you are "paying for" when you buy the stock. A P/E of 20 means you pay $20 for every $1 of annual earnings. The S&P 500 historically trades at an average P/E of roughly 15–17. A P/E significantly above that may signal high growth expectations; one below may indicate undervaluation — or declining business quality.

Price-to-Sales Ratio (P/S)

The P/S ratio divides market capitalization by total revenue. Unlike the P/E ratio, it works even for companies that are not yet profitable, making it essential for evaluating high-growth firms. A P/S below 1.0 may indicate undervaluation, while ratios above 10 are typically reserved for fast-growing tech or SaaS companies with high expected future margins.

Price-to-EBIT Ratio

This ratio relates Stryker's market price to its operating earnings, excluding the effects of debt structure and tax jurisdiction. It is particularly useful for comparing companies across different countries or with different levels of leverage, because it focuses purely on operational profitability. Lower values suggest cheaper operational earnings.

How to Use This Chart

This chart plots Stryker's valuation multiples over time. Compare the current P/E, P/S, and P/EBIT to their own historical averages — if the current ratio is well below the multi-year average, the stock may be relatively cheap compared to its own track record. Combine this with industry comparisons: a P/E that looks high in absolute terms may be justified if Stryker grows earnings faster than its peers.

Stryker Stock analysis

What does Stryker do? Stryker Corp is a global medical technology company based in Kalamazoo, Michigan, USA. It was founded by Dr. Homer Stryker in 1941 and has since become one of the world's leading providers of medical devices, implants, and medical instruments and accessories. The history of Stryker Corp began over 80 years ago with the invention of the "Gipsbruch", a device developed by Dr. Homer Stryker to better treat broken bones. The Gipsbruch marked the beginning of a new era in orthopedics and led to a comprehensive redefinition of patient care. Over the following decades, Stryker Corp developed further life-saving products and solutions that are used worldwide. Stryker Corp offers a wide range of medical devices, implants, instruments, and accessories to support patient care. The company pursues a strategic growth strategy focused on innovation and acquisitions. This includes the development and marketing of new technologies to enhance patients' quality of life. Stryker Corp is divided into three main divisions: Orthopedics, Medical Technology, and Neurotechnology. The Orthopedics division specializes in the development and manufacturing of implants, instruments, and devices for the treatment of musculoskeletal disorders. The Medical Technology division focuses on the development and manufacturing of devices to support surgical procedures and diagnostics in areas such as endoscopy and emergency medicine. The Neurotechnology division specializes in the development and manufacturing of products for the treatment of neurological disorders such as epilepsy, Parkinson's disease, and hydrocephalus. Some of Stryker Corp's well-known products include the Gipsbruch, which has become a standard device in orthopedics. Other significant products include the hip implant system and the knee implant system, which are widely used and successful in many countries worldwide. Another product of Stryker Corp is the Neptune System, a surgical system that enables the safe and effective use of fluids and gases during surgical procedures. Overall, Stryker Corp is a global medical technology company that originated from the invention of the Gipsbruch and is now one of the leading companies in the manufacturing and development of medical devices and instruments. The company pursues a growth strategy based on innovation and acquisitions and has already produced many successful products. The different divisions, Orthopedics, Medical Technology, and Neurotechnology, each focus on different medical disciplines and offer a wide range of products and solutions to support patient care. Stryker is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Stryker stock

EV/EBIT (Enterprise Value to EBIT) of Stryker is 26.01 in 2025.

EV/EBIT (Enterprise Value to EBIT) of Stryker changed from 25.13 to 26.01, representing a 3.52% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of EV/EBIT (Enterprise Value to EBIT) Stryker since 2006 – with annual values, charts, and detailed analysis.

The EV/EBIT ratio measures a company's enterprise value relative to its operating earnings. It accounts for debt, making it useful for comparing companies with different capital structures.

EV/EBIT = Enterprise Value / Earnings Before Interest and Taxes

To evaluate EV/EBIT (Enterprise Value to EBIT)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for EV/EBIT (Enterprise Value to EBIT).

A 'good' varies by industry and company stage. On Eulerpool, you can compare EV/EBIT (Enterprise Value to EBIT)'s Stryker with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Valuation — Stryker

All Key Metrics — Stryker